Barclays’s Cantel Medical Corporation CMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-104,332
| Closed | -$8.33M | – | 5184 |
|
|
2021
Q1 | $8.33M | Buy |
104,332
+85,938
| +467% | +$6.71M | ﹤0.01% | 1168 |
|
|
2020
Q4 | $1.45M | Sell |
18,394
-21,313
| -54% | -$1.25M | ﹤0.01% | 2494 |
|
|
2020
Q3 | $1.75M | Sell |
39,707
-34,446
| -46% | -$1.7M | ﹤0.01% | 2222 |
|
|
2020
Q2 | $3.28M | Sell |
74,153
-29,575
| -29% | -$1.1M | ﹤0.01% | 1697 |
|
|
2020
Q1 | $3.72M | Buy |
103,728
+48,506
| +88% | +$2.76M | ﹤0.01% | 1720 |
|
|
2019
Q4 | $3.92M | Buy |
55,222
+15,990
| +41% | +$1.16M | ﹤0.01% | 2277 |
|
|
2019
Q3 | $2.93M | Buy |
39,232
+14,541
| +59% | +$1.23M | ﹤0.01% | 2408 |
|
|
2019
Q2 | $1.99M | Buy |
24,691
+18,406
| +293% | +$1.29M | ﹤0.01% | 2926 |
|
|
2019
Q1 | $421K | Sell |
6,285
-14,141
| -69% | -$1.07M | ﹤0.01% | 4270 |
|
|
2018
Q4 | $1.52M | Sell |
20,426
-1,751
| -8% | -$145K | ﹤0.01% | 2686 |
|
|
2018
Q3 | $2.04M | Sell |
22,177
-32,755
| -60% | -$3.12M | ﹤0.01% | 2852 |
|
|
2018
Q2 | $5.4M | Buy |
54,932
+45,752
| +498% | +$5.12M | ﹤0.01% | 1664 |
|
|
2018
Q1 | $1.02M | Buy |
9,180
+1,893
| +26% | +$212K | ﹤0.01% | 3190 |
|
|
2017
Q4 | $749K | Buy |
7,287
+3,247
| +80% | +$323K | ﹤0.01% | 3404 |
|
|
2017
Q3 | $381K | Sell |
4,040
-274
| -6% | -$21.6K | ﹤0.01% | 3877 |
|
|
2017
Q2 | $336K | Buy |
4,314
+3,593
| +498% | +$270K | ﹤0.01% | 3892 |
|
|
2017
Q1 | $57K | Sell |
721
-479
| -40% | -$38.1K | ﹤0.01% | 5268 |
|
|
2016
Q4 | $94K | Sell |
1,200
-1,082
| -47% | -$84.1K | ﹤0.01% | 4796 |
|
|
2016
Q3 | $178K | Sell |
2,282
-5,509
| -71% | -$400K | ﹤0.01% | 4056 |
|
|
2016
Q2 | $535K | Buy |
+7,791
| New | +$537K | ﹤0.01% | 3156 |
|
|
2016
Q1 | – | Sell |
-290
| Closed | -$18K | – | 6565 |
|
|
2015
Q4 | $18K | Sell |
290
-39
| -12% | -$2.38K | ﹤0.01% | 5226 |
|
|
2015
Q3 | $18K | Sell |
329
-12,989
| -98% | -$688K | ﹤0.01% | 5518 |
|
|
2015
Q2 | $706K | Buy |
13,318
+10,320
| +344% | +$502K | ﹤0.01% | 3184 |
|
|
2015
Q1 | $141K | Sell |
2,998
-1,879
| -39% | -$83.2K | ﹤0.01% | 4607 |
|
|
2014
Q4 | $209K | Buy |
4,877
+3,314
| +212% | +$135K | ﹤0.01% | 4601 |
|
|
2014
Q3 | $53K | Buy |
1,563
+957
| +158% | +$33.8K | ﹤0.01% | 5842 |
|
|
2014
Q2 | $22K | Sell |
606
-779
| -56% | -$26.4K | ﹤0.01% | 6464 |
|
|
2014
Q1 | $45K | Sell |
1,385
-13,299
| -91% | -$439K | ﹤0.01% | 6092 |
|
|
2013
Q4 | $485K | Sell |
14,684
-5,836
| -28% | -$202K | ﹤0.01% | 4126 |
|
|
2013
Q3 | $636K | Sell |
20,520
-4,233
| -17% | -$113K | ﹤0.01% | 3844 |
|
|
2013
Q2 | $559K | Buy |
+24,753
| New | +$536K | ﹤0.01% | 4074 |
|
Barclays's CMD Position: Q2 2021 in Review
Barclays sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 104,332 shares — an estimated $8.33M sold.
Barclays first reported a position in CMD in Q2 2013 and held it in 31 quarters. The position peaked at $8.33M in Q1 2021. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.
- Barclays reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
- Barclays sold 104,332 Cantel Medical Corporation shares in Q2 2021, an estimated $8.33M.
- Barclays first reported a position in Cantel Medical Corporation in Q2 2013 and held it in 31 quarters.
- Barclays's Cantel Medical Corporation position peaked at $8.33M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.